NCT02508623.

Study name	Effect of administration of rifaximin on the portal pressure of patients with liver cirrhosis and oesophageal varices (ERASE)
Methods	Randomised, parallel assignment, double‐blind (participant, caregiver, investigator, outcomes assessor), phase 3 trial
Participants	People with cirrhosis and presence of oesophageal varices at high risk of bleeding (60 participants)
Interventions	Intervention: rifaximin (550 mg 1 tablet twice daily for 60 days) Control intervention: placebo (Placebo 1 tablet twice daily for 60 days)
Outcomes	Change of hepatic venous pressure gradient, cognitive function, systemic inflammatory response and modification of faecal bacteria
Starting date	2014
Contact information	Piero Amodio ‐‐PI has retired Francesca Campagna his colleague remains in post Claudio Dario francescacampagna3@gmail.com Tel: +39 0498218675 /+39 0498212105 University of Padua, Italy
Notes	Outcome data from this study, if completed, could be included in future versions of this review